Proarrhythmia assessment is one of the major concerns for regulatory bodies and pharmaceutical industry. ICH guidelines recommending preclinical tests have been established in attempt to eliminate the risk of drug-induced arrhythmias. | Drug-drug interactions and QT prolongation as a commonly assessed cardiac effect - comprehensive overview of clinical trials